Literature DB >> 21208102

PARP and cancer--if it's broke, don't fix it.

Lisa A Carey, Norman E Sharpless.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21208102      PMCID： PMC3712751          DOI： 10.1056/NEJMe1012546

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

Review 1.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

2.  PARP1 deficiency exacerbates diet-induced obesity in mice.

Authors:  Kishor Devalaraja-Narashimha; Babu J Padanilam
Journal:  J Endocrinol       Date:  2010-03-25       Impact factor: 4.286

Review 3.  Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics.

Authors:  Jin-xue He; Chun-hao Yang; Ze-hong Miao
Journal:  Acta Pharmacol Sin       Date:  2010-08-02       Impact factor: 6.150

4.  Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

Authors:  Joyce O'Shaughnessy; Cynthia Osborne; John E Pippen; Mark Yoffe; Debra Patt; Christine Rocha; Ingrid Chou Koo; Barry M Sherman; Charles Bradley
Journal:  N Engl J Med       Date:  2011-01-05       Impact factor: 91.245

5.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

Authors:  Andrew Tutt; Mark Robson; Judy E Garber; Susan M Domchek; M William Audeh; Jeffrey N Weitzel; Michael Friedlander; Banu Arun; Niklas Loman; Rita K Schmutzler; Andrew Wardley; Gillian Mitchell; Helena Earl; Mark Wickens; James Carmichael
Journal:  Lancet       Date:  2010-07-06       Impact factor: 79.321

Review 6.  The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets.

Authors:  Raga Krishnakumar; W Lee Kraus
Journal:  Mol Cell       Date:  2010-07-09       Impact factor: 17.970

7.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Authors:  Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono
Journal:  N Engl J Med       Date:  2009-06-24       Impact factor: 91.245

8.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Authors:  Hannah Farmer; Nuala McCabe; Christopher J Lord; Andrew N J Tutt; Damian A Johnson; Tobias B Richardson; Manuela Santarosa; Krystyna J Dillon; Ian Hickson; Charlotte Knights; Niall M B Martin; Stephen P Jackson; Graeme C M Smith; Alan Ashworth
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504
  8 in total
  20 in total

1.  Targeting the missing links for cancer therapy.

Authors:  Kornelia Polyak; Judy Garber
Journal:  Nat Med       Date:  2011-03       Impact factor: 53.440

2.  A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.

Authors:  Arun Rajan; Corey A Carter; Ronan J Kelly; Martin Gutierrez; Shivaani Kummar; Eva Szabo; Mary Ann Yancey; Jiuping Ji; Baskar Mannargudi; Sukyung Woo; Shawn Spencer; William Douglas Figg; Giuseppe Giaccone
Journal:  Clin Cancer Res       Date:  2012-02-27       Impact factor: 12.531

3.  Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.

Authors:  J Chad Brenner; Bushra Ateeq; Yong Li; Anastasia K Yocum; Qi Cao; Irfan A Asangani; Sonam Patel; Xiaoju Wang; Hallie Liang; Jindan Yu; Nallasivam Palanisamy; Javed Siddiqui; Wei Yan; Xuhong Cao; Rohit Mehra; Aaron Sabolch; Venkatesha Basrur; Robert J Lonigro; Jun Yang; Scott A Tomlins; Christopher A Maher; Kojo S J Elenitoba-Johnson; Maha Hussain; Nora M Navone; Kenneth J Pienta; Sooryanarayana Varambally; Felix Y Feng; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2011-05-17       Impact factor: 31.743

Review 4.  BRCA mutation testing in determining breast cancer therapy.

Authors:  Karen Lisa Smith; Claudine Isaacs
Journal:  Cancer J       Date:  2011 Nov-Dec       Impact factor: 3.360

Review 5.  Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.

Authors:  Ingrid Lilienthal; Nikolas Herold
Journal:  Int J Mol Sci       Date:  2020-09-19       Impact factor: 5.923

Review 6.  Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.

Authors:  Cormac Owens; Lesleigh S Abbott; Abha A Gupta
Journal:  Paediatr Drugs       Date:  2013-12       Impact factor: 3.022

7.  Management options in triple-negative breast cancer.

Authors:  Christina A Minami; Debra U Chung; Helena R Chang
Journal:  Breast Cancer (Auckl)       Date:  2011-07-27

8.  Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients.

Authors:  See-Hyoung Park; Sang Jae Noh; Kyoung Min Kim; Jun Sang Bae; Keun Sang Kwon; Sung Hoo Jung; Jung Ryul Kim; Ho Lee; Myoung Ja Chung; Woo Sung Moon; Myoung Jae Kang; Kyu Yun Jang
Journal:  Transl Oncol       Date:  2015-08       Impact factor: 4.243

9.  Treating breast cancer in the 21st century: emerging biological therapies.

Authors:  Gabriel Tinoco; Sean Warsch; Stefan Glück; Kiran Avancha; Alberto J Montero
Journal:  J Cancer       Date:  2013-01-11       Impact factor: 4.207

10.  PARP inhibitors: current status and implications for anticancer therapeutics.

Authors:  Hadi Usmani; Syed Ather Hussain; Asfandyar Sheikh
Journal:  Infect Agent Cancer       Date:  2013-12-02       Impact factor: 2.965
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.